Researchers at Memorial Sloan-Kettering Cancer Center (MSKCC) have completed the largest genomic analysis of prostate tumors to date. The results, based on clinical and genomic information collected from 218 patients, provide an overview of the common genetic changes in the disease and point to new directions for research, including a way to potentially differentiate aggressive tumors from those that are not life threatening. The researchers have made the data available to the community through a public Web site, and a summary of the results appeared online last week in Cancer Cell. Read more > >
I was pleasantly surprised and very gratified that this year’s Fifth Biennial Cancer Survivorship Research Conference, held June 17–19 in Washington, DC, was our biggest meeting yet. Despite a weak economy and many competing scientific meetings, more than 550 researchers, patient advocates, cancer care specialists, public health officials, and others attended from 44 states, the District, Guam, and a number of foreign countries. This is testament to the rapid growth and evolution within the field of cancer survivorship, both in the rigor of scientific inquiry being pursued and the numbers of those engaged in research and care that addresses the long-term needs of cancer survivors. Read more > >
- Leukemia Drug Pulled from U.S. Market
- New Treatment Approved for Advanced Prostate Cancer that Resists Docetaxel
- Nilotinib Approved to Treat Rare Form of Chronic Myeloid Leukemia
- ODPHP Releases Health Literacy Guide
- DCB Launches Updated Web Site
- Fourth Telephone Workshop for Cancer Survivors Slated for July 13
- NCI Program Will Aid Development and Validation of Trial Assays
- Budget, Clinical Trials, and Training Highlighted at NCAB Meeting
- NCI Scientists Awarded 2010 Federal Laboratory Consortium Awards
- PARADE Magazine Spotlights Cancer in America
- NCI and Chinese Academy of Medical Sciences Host caBIG Workshop
Selected articles from past issues of the NCI Cancer Bulletin are available in Spanish.
The NCI Cancer Bulletin is produced by the National Cancer Institute (NCI), which was established in 1937. Through basic, clinical, and population-based biomedical research and training, NCI conducts and supports research that will lead to a future in which we can identify the environmental and genetic causes of cancer, prevent cancer before it starts, identify cancers that do develop at the earliest stage, eliminate cancers through innovative treatment interventions, and biologically control those cancers that we cannot eliminate so they become manageable, chronic diseases.
For more information about cancer, call 1-800-4-CANCER or visit http://www.cancer.gov.
NCI Cancer Bulletin staff can be reached at email@example.com.